Nov 2022 $6 M Private placement after listing $2 to $10 million 2
InMed Pharmaceuticals Inc.: Private sale, Nov 2022 × Investors in this round 2 investors had bought by the notice of Dec 6, 2022: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $450,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in British Columbia, Canada People named in the notice Alexandra D.J. Mancini · Executive Officer Eric A. Adams · Executive Officer, Director Eric C. Hsu · Executive Officer Michael D.J. Woudenberg · Executive Officer Sarah A. Li · Executive Officer Andrew J. Hull · Director Bryan J. Baldasare · Director Janet J. Grove · Director Nicole J. Lemerond · Director William J. Garner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in all US states Remarks in the notice On fees: “In addition to the $450,000, the issuer paid to the sole placement agent in the offering, a management fee of $60,000, $20,000 for non-accountable expenses and $35,000 for fees and expenses of legal counsel and other out-of-pocket expenses.”On the amounts: “Consists of (i) $6,000,010.50 received and (ii) approximately $166.82 to be received upon exercise of pre-funded warrants sold in the offering to purchase up to an aggregate of 1,668,185 common shares at an exercise price of $0.0001 per share.”Signed by Eric A. Adams, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 6, 2022. Read the notice at the SEC .
equity, options SEC Jun 2022 $5 M Private placement after listing $2 to $10 million 1
InMed Pharmaceuticals Inc.: Private sale, Jun 2022 × Investors in this round 1 investor had bought by the notice of Jun 8, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $375,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in British Columbia, Canada People named in the notice Alexandra D.J. Mancini · Executive Officer Brenda A. Edwards · Executive Officer Eric A. Adams · Executive Officer, Director Eric C. Hsu · Executive Officer Michael C. Woudenberg · Executive Officer Adam J. Cutler · Director Andrew J. Hull · Director Bryan J. Baldasare · Director Janet J. Grove · Director William J. Garner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round ROTH Capital Partners, LLC (CRD 15407) · Newport Beach, California Sold in all US states H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in all US states Signed by Eric A. Adams, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 8, 2022. Read the notice at the SEC .
equity, options SEC Oct 2021 $4 M Issued in a merger or acquisition $2 to $10 million 54
InMed Pharmaceuticals Inc.: Private sale, Oct 2021 × Investors in this round 54 investors had bought by the notice of Oct 28, 2021: 52 accredited, 2 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in British Columbia, Canada People named in the notice Alexandra D.J. Mancini · Executive Officer Bruce S. Colwill · Executive Officer Eric A. Adams · Executive Officer, Director Eric C. Hsu · Executive Officer Michael C. Woudenberg · Executive Officer Adam A. Cutler · Director Andrew A. Hull · Director Catherine A. Sazdanoff · Director William J. Garner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offering made to prior stockholders of BayMedica, Inc., as part of the merger consideration. Total amount sold based on a per share price of $2.10.”On a merger: “Offering made to prior stockholders of BayMedica, Inc., as part of the merger consideration.”Signed by Bruce S. Colwill, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 28, 2021. Read the notice at the SEC .
equity SEC Jul 2021 $12 M No. 2 $10 to $50 million 1
InMed Pharmaceuticals Inc.: Raise no. 2, Jul 2021 × Investors in this round 1 investor had bought by the notice of Jul 19, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $12 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $900,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in British Columbia, Canada People named in the notice Alexandra D.J. Mancini · Executive Officer Bruce S. Colwill · Executive Officer Eric A. Adams · Executive Officer, Director Eric C. Hsu · Executive Officer Michael C. Woudenberg · Executive Officer Adam A. Cutler · Director Andrew A. Hull · Director Catherine A. Sazdanoff · Director William J. Garner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in all US states ROTH Capital Partners, LLC (CRD 15407) · Newport Beach, California Sold in all US states Signed by Eric A. Adams, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 19, 2021. Read the notice at the SEC .
equity, options SEC Jan 2018 $2 M No. 1 Under $2 million 2
InMed Pharmaceuticals Inc.: Raise no. 1, Jan 2018 × Investors in this round 2 investors had bought by the notice of Jan 17, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Units, each comprised of one common share and one share purchase warrant exercisable at CAD$1.25 for 18 months Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue No revenue
Sales commissions none
Finders' fees $67,722
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in British Columbia, Canada People named in the notice Alexandra D.J. Mancini · Executive Officer Eric A. Adams · Executive Officer, Director Jeff J. Charpentier · Executive Officer Sazzad J. Hossain · Executive Officer Adam A. Cutler · Director Andrew J. Hull · Director Martin A. Bott · Director William J. Garner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Canaccord Genuity Corp. · broker-dealer Canaccord Genuity Inc. (CRD 1020) · New York, New York Sold in NY Remarks in the notice On the amounts: “US dollar amounts herein have been converted from Canadian dollars based on the 0.7979 Bank of Canada daily exchange rate in effect on 1-3-18. Total Remaining to be Sold represents the aggregate exercise price of all warrants sold in the offering.”On the use of proceeds: “Proceeds from the offering may be used for general working capital purposes. Thus, proceeds may be used for payments to officers and directors in the ordinary course, but they are not specifically earmarked for such payments.”Signed by Jeff Charpentier, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 17, 2018. Read the notice at the SEC .
equity, options SEC